Going the Wrong Way: How Arizona's Overdose Deaths Climbed While the Country's Fell

In January 2025, Maricopa County recorded more opioid-related deaths than in any January going back to 2018. February was worse than any prior February. March was the worst March on record. April, the same. By August, Arizona’s total drug overdose death count was 20 percent higher than the same period in 2024. Over 2,000 Arizonans died of opioid-related causes in 2025 alone — up from about 1,700 the year before. At current Maricopa County rates, that works out to more than three people per day. Every day.

On May 13, the CDC’s National Center for Health Statistics released its provisional overdose data for 2025, and the headline was, for once, legitimately hopeful: U.S. drug overdose deaths fell for the third consecutive year, from an estimated 81,313 in 2024 to 69,973 in 2025. A 14 percent decline. Forty-four states went down. The opioid death count dropped from 55,296 to 44,564. Analysts cautioned the data was provisional and likely to be revised, but the direction was clear and sustained. Something was working — a combination of expanded naloxone access, MAT saturation in high-burden states, and changes in the fentanyl supply chain that reduced the concentration of the drug reaching users in parts of the country.

Arizona was not one of those parts. New Mexico was not. Colorado was not.

While the country moved one direction, the Southwest moved the other. Arizona posted a 17.31 percent increase in overdose deaths for the full year measured through May 2026. New Mexico posted 21.30 percent. Colorado, 10 percent or more. A peer-reviewed analysis of Arizona’s monthly death totals, published in Drug and Alcohol Dependence in May 2026, found that January, February, March, and April 2025 each reached the highest recorded totals for those months across every year studied from 2018 onward. These weren’t statistical blips. They were a sustained divergence from a national trend that nearly everyone else was benefiting from.

The question worth asking — the one that matters for anyone doing harm reduction work in Phoenix, or running a treatment facility in Tucson, or trying to figure out where Rize Recovery should build its infrastructure — is why. Why Arizona? Why now? Why worse, when nearly everywhere else is better?

The geography of supply explains a lot

Arizona does not have a substance use crisis that happens to involve fentanyl. Arizona has a fentanyl crisis that involves substance use. The distinction matters because it changes the analysis entirely.

In March 2026, the DEA completed a month-long interdiction operation and disclosed that the majority of the fentanyl seized came from Arizona. Not from the border crossings of Texas or California, which handle higher absolute volumes of freight — but from Arizona’s drug trafficking corridors, which have become the primary distribution network for fentanyl moving from Sinaloa Cartel manufacturing into the U.S. heartland. Arizona is not only consuming fentanyl at crisis levels; it is the transit hub for much of the fentanyl that goes everywhere else. That geographic reality means the local drug supply is more contaminated, more available, and more varied in concentration than almost anywhere in the country.

Fentanyl was involved in 59 percent of Maricopa County’s fatal overdoses in 2024. Methamphetamine was involved in 67 percent. That’s not a misprint: those percentages overlap because polysubstance overdoses — fentanyl combined with meth, or with benzodiazepines, or with bromazolam — now account for the majority of deaths. The pure opioid overdose, the kind that naloxone reliably reverses, is increasingly the exception. The combination overdose, which may require multiple naloxone doses and still results in death, is the rule.

The nationwide fentanyl supply did change in 2024 and 2025 — enforcement disruptions and cartel restructuring produced a period when the drug was less potent and less consistent in some markets, contributing to the national decline. Arizona, sitting at the distribution center of that supply chain, absorbed more volatility than stability. When the supply fluctuates, users who have calibrated their tolerance to a certain concentration get hit by batches they didn’t expect.

When the supply fluctuates, users who have calibrated their tolerance to a certain concentration get hit by batches they didn’t expect.

49th out of 51, and it shows

The drug supply problem is structural and largely outside the state’s control. The treatment infrastructure problem is structural and entirely within it.

Arizona consistently ranks 49th out of 51 states and territories for behavioral health access. Among the metrics that compound this ranking: fewer than 1 in 20 Arizonans with opioid use disorder receive medications like buprenorphine or methadone. That number should land with force. Medication-assisted treatment is the most evidence-supported intervention for OUD — it cuts overdose risk by 50 percent or more, reduces criminal legal involvement, and improves long-term recovery outcomes. In Ohio, Kentucky, and West Virginia — states that drove the earliest peaks of the opioid crisis and have built significant treatment infrastructure in response — MAT access has improved meaningfully over the past decade. In Arizona, it remains a rarity.

AHCCCS, Arizona’s Medicaid program, covers substance use treatment including MAT. The coverage is there. The providers are not. There are not enough buprenorphine prescribers in the state, not enough methadone clinics in rural counties, not enough residential programs that accept Medicaid without a multi-month waitlist. The AHCCCS Annual Substance Use Treatment Report, submitted to Governor Hobbs on April 28, 2026, documented that approximately 6–7 percent of Arizona’s population met criteria for a substance use disorder but did not receive treatment. That’s roughly 500,000 people who need services the state can’t provide at scale.

Arizona will receive $1.215 billion over 18 years from opioid lawsuit settlements — $526 million to the state, $669 million to counties. Maricopa County has begun disbursing those funds: $4.3 million across 17 organizations in April 2025. That’s a meaningful down payment on a genuine harm reduction infrastructure. It is not remotely proportionate to the scale of what’s needed. At 17 percent annual increases, the math runs in the wrong direction.

The problem with settlement funds distributed on an 18-year timeline is that people are dying today. The infrastructure being built in year three will serve the crisis in year seven — if the funding cadence holds, if oversight bodies don’t redirect the money, if the organizations receiving the grants survive the federal funding environment long enough to deploy it. All three of those contingencies are live risks in 2026.

The deaths are not evenly distributed

The 17 percent statewide increase conceals a story about which Arizonans are dying at higher rates. The Drug and Alcohol Dependence analysis found that the percent increases from 2024 to 2025 were highest among Hispanic and Black Arizonans. Not by a small margin. This is consistent with a pattern documented nationally: communities of color were already disproportionately impacted by overdose mortality relative to their treatment access, and the recent national improvement has not erased — and in some states has widened — those disparities.

In Maricopa County, which contains Phoenix and accounts for roughly 60 percent of Arizona’s population, the overdose crisis maps closely onto geography of poverty and housing instability. The zip codes with the highest death rates are the same zip codes with the fewest treatment facilities accepting AHCCCS, the fewest sober living homes with licensed oversight, and the fewest harm reduction services. The spatial gap between who needs care and where care is located is not an accident; it reflects decades of facility-siting decisions that concentrated treatment in areas where providers could ensure payment and minimize neighborhood opposition.

Youth exposure compounds the geographic inequity. Arizona youth and young adults have experienced overdose mortality at roughly twice the national average, driven heavily by counterfeit pills laced with fentanyl that circulate through high school social networks. A 16-year-old in Phoenix who believes they’re taking a pressed OxyContin from a friend is taking a pill that is, statistically, more likely to contain fentanyl than oxycodone. There is no safe way to take a pill with unknown provenance, and fentanyl test strips — which can at least confirm the presence of the drug — are still not universally available in schools or through community harm reduction programs at the scale the need demands.

A 16-year-old in Phoenix who believes they’re taking a pressed OxyContin from a friend is taking a pill that is, statistically, more likely to contain fentanyl than oxycodone.

Settlement funds are real. Time is not.

The national overdose decline is real. It represents genuine lives saved, genuine policy work paying off, genuine community-level harm reduction infrastructure finally reaching critical mass. Arizona should not be excluded from those gains — and the work underway, from AHCCCS coverage expansions to sober living oversight legislation passed in 2025 to the early deployment of settlement funds, represents real effort by people who understand the scale of the problem.

But January 2025 was the worst January on record. February was worse than that. And the structural conditions — drug supply geography, treatment access rankings, demographic disparities, youth exposure — have not changed materially in the six months since.

For Arizonans who are currently using, who are trying to find treatment, who are watching someone they love cycle through detox and relapse and detox again: the national headline is not your headline. Your headline is that your state is going the wrong way, and the window for the settlement funds to change that trajectory is already narrowing. What happens in the next 18 months of overdose data — whether Arizona joins the national decline or continues to diverge — will depend less on any single policy or program than on whether the treatment infrastructure gets built fast enough to meet the need that’s already there.

Three people a day in Maricopa County alone. That’s the number that should be on the wall of every behavioral health planning meeting in Phoenix. Not the national figure. This one.

Rize Recovery tracks treatment access across Arizona’s 100+ AHCCCS-covered facilities. If you or someone you know is looking for treatment options, start at rizerecovery.com/find-help.